TOKYO, May 12 (Pulse News Wire) – Olympus Corporation (7733.T) reported its consolidated financial guidance for the fiscal year ending March 31, 2026. The company expects revenue to range from ¥1,010.68 billion to ¥1,055 billion, with adjusted operating profit forecast between ¥186.5 million and ¥205.5 million.
For the medical business segment, which includes Gastrointestinal Solutions Division (GIS) and Surgical and Interventional Solutions Division (SIS), Olympus projects revenue of up to ¥1,055 billion. Adjusted operating profit for the medical business is expected to fall within a range of ¥186.5 million to ¥205.5 million.
In the quarter ending March 31, 2026, Olympus anticipates revenue of ¥1,010.68 billion, compared to ¥997.33 billion in the prior year. The company's adjusted operating profit is forecast at ¥164.34 million, down slightly from ¥168.81 million in the same period last year.
Olympus noted that the restructuring of its endoscopic solutions and therapeutic solutions divisions into GIS and SIS has led to adjustments in corporate expenses, impacting the allocation of certain costs to these newly defined segments.
🟢 Confidence: High AI-translated content.